GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Shiller PE Ratio

Affimed NV (Affimed NV) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Affimed NV Shiller PE Ratio Historical Data

The historical data trend for Affimed NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Shiller PE Ratio Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Affimed NV's Shiller PE Ratio

For the Biotechnology subindustry, Affimed NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's Shiller PE Ratio falls into.



Affimed NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Affimed NV's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Affimed NV's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.516/123.6675*123.6675
=-1.516

Current CPI (Dec. 2023) = 123.6675.

Affimed NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -9.023 99.543 -11.210
201406 8.160 99.543 10.138
201409 5.670 99.823 7.024
201412 -2.713 99.543 -3.371
201503 -0.649 99.717 -0.805
201506 -2.132 100.417 -2.626
201509 -2.694 100.417 -3.318
201512 -2.070 99.717 -2.567
201603 -2.784 100.017 -3.442
201606 -2.697 100.717 -3.312
201609 -3.479 101.017 -4.259
201612 -1.688 101.217 -2.062
201703 -2.032 101.417 -2.478
201706 -2.022 102.117 -2.449
201709 -2.145 102.717 -2.582
201712 -1.657 102.617 -1.997
201803 -1.850 102.917 -2.223
201806 -1.519 104.017 -1.806
201809 -2.217 104.718 -2.618
201812 1.706 104.217 2.024
201903 0.339 104.217 0.402
201906 -1.921 105.718 -2.247
201909 -1.872 106.018 -2.184
201912 -2.111 105.818 -2.467
202003 -1.215 105.718 -1.421
202006 -1.802 106.618 -2.090
202009 -0.824 105.818 -0.963
202012 -2.068 105.518 -2.424
202103 0.119 107.518 0.137
202106 -1.928 108.486 -2.198
202109 -1.647 109.435 -1.861
202112 -2.158 110.384 -2.418
202203 -1.542 113.968 -1.673
202206 -1.374 115.760 -1.468
202209 -1.089 118.818 -1.133
202212 -2.373 119.345 -2.459
202303 -2.248 122.402 -2.271
202306 -2.167 123.140 -2.176
202309 -1.708 124.195 -1.701
202312 -1.516 123.668 -1.516

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affimed NV  (NAS:AFMD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Affimed NV Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Affimed NV's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (Affimed NV) Business Description

Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (Affimed NV) Headlines

From GuruFocus